Novo Holdings and Lundbeckfonden Portfolio Company IO Biotech Closes Initial Public Offering on the Nasdaq Global Market

  • Incubated and supported by Denmark’s largest biotech investors, Lundbeckfonden and Novo Holdings
  • Lundbeckfonden co-led the Series A financing in 2015 together with Novo Holdings, and is the largest shareholder
  • Novo Holdings created and launched IO Biotech with first seed investment in 2015

Copenhagen, Denmark – 9 November 2021 – Novo Holdings, a leading international life science investor, and Lundbeckfonden, one of Denmark’s largest commercial foundations funding biomedical sciences research, today note the update from portfolio company IO Biotech Inc. (“IO Biotech”), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform.  IO Biotech announced the closing of its Initial Public Offering (IPO) of 8,222,500 shares of common stock at a public offering price of $14.00 per share, for gross proceeds of $115.1 million, after deducting underwriting discounts and offering expenses. The shares are trading on the Nasdaq Global Market under the ticker symbol “IOBT.”

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...